These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3046413)

  • 21. Cardiac drugs: new inotropes.
    Kelleher RM
    Crit Care Nurs Clin North Am; 1989 Jun; 1(2):391-7. PubMed ID: 2818883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of three phosphodiesterase type III inhibitors on mechanical and metabolic function in guinea pig isolated hearts.
    Zausig YA; Stowe DF; Zink W; Grube C; Martin E; Graf BM
    Anesth Analg; 2006 Jun; 102(6):1646-52. PubMed ID: 16717301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amrinone in severe congestive heart failure: another look at an intriguing new cardioactive drug.
    Hermiller JB; Leithe ME; Magorien RD; Unverferth DV; Leier CV
    J Pharmacol Exp Ther; 1984 Feb; 228(2):319-26. PubMed ID: 6694112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Amrinone (50 micrograms.kg-1.min-1) does not impair regional myocardial tissue metabolism during the 40%-decrease of left anterior descending coronary flow].
    Tateyama T; Suzuki H; Fukuyama H; Fujiwara R; Abe Y; Okutsu Y
    Masui; 1996 Feb; 45(2):148-52. PubMed ID: 8865700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of intravenous amrinone: the first of a new class of positive inotropic agents with vasodilator properties.
    Bottorff MB; Rutledge DR; Pieper JA
    Pharmacotherapy; 1985; 5(5):227-37. PubMed ID: 3906583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular effects of a phosphodiesterase III inhibitor, amrinone, in infants: non-invasive echocardiographic evaluation.
    Teshima H; Tobita K; Yamamura H; Takeda A; Motomura H; Nakazawa M
    Pediatr Int; 2002 Jun; 44(3):259-63. PubMed ID: 11982892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human platelet Ca2+ mobilization, glycoprotein IIb/IIIa activation, and experimental coronary thrombosis in vivo in dogs are all inhibited by the inotropic agent amrinone.
    Sill JC; Bertha B; Berger I; Uhl C; Nugent M; Folts J
    Circulation; 1997 Sep; 96(5):1647-53. PubMed ID: 9315560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The acute effect of a new positive inotropic agent (AR-L 115 BS) on cardiac hemodynamics and contractility in patients with severe chronic congestive heart failure.
    Hauf GF; Bubenheimer P; Roskamm H
    Arzneimittelforschung; 1981; 31(1a):253-6. PubMed ID: 7195235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amrinone. A preliminary review of its pharmacological properties and therapeutic use.
    Ward A; Brogden RN; Heel RC; Speight TM; Avery GS
    Drugs; 1983 Dec; 26(6):468-502. PubMed ID: 6360634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular basis for the cardiovascular activities of amrinone and AR-L57.
    Hayes JS; Bowling N; Boder GB; Kauffman R
    J Pharmacol Exp Ther; 1984 Jul; 230(1):124-32. PubMed ID: 6086873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pharmacotherapy of severe heart failure with inodilators--new approaches].
    Baumann G; Hader O
    Z Kardiol; 1996; 85 Suppl 4():9-19. PubMed ID: 9027110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diminished inotropic response to amrinone in ventricular myocytes from myopathic hamsters is linked to depression of high-gain Ca2+-induced Ca2+ release.
    Xiong W; Ferrier GR; Howlett SE
    J Pharmacol Exp Ther; 2004 Aug; 310(2):761-73. PubMed ID: 15064331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro and in vivo studies of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212), a novel positive inotropic drug, in various animals.
    Yamashita S; Hosokawa T; Kojima M; Mori T; Yabuuchi Y
    Arzneimittelforschung; 1984; 34(3A):342-6. PubMed ID: 6331464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure.
    Sabbah HN; Imai M; Cowart D; Amato A; Carminati P; Gheorghiade M
    Am J Cardiol; 2007 Jan; 99(2A):41A-46A. PubMed ID: 17239704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hemodynamic effects of amrinone combined with dopamine in patients undergoing living renal transplantation].
    Okuno Y; Mashimo T; Takashina M; Hagihira S; Inagaki Y; Mori T; Yoshiya I
    Masui; 1997 Jan; 46(1):87-94. PubMed ID: 9028089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amrinone: is it the inotrope of choice?
    Wynands JE
    J Cardiothorac Anesth; 1989 Dec; 3(6 Suppl 2):45-57. PubMed ID: 2521051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Hemodynamic effects of amrinone, dobutamine and dopamine in the cardiac low output syndrome following open-heart surgery].
    Husedzinović I; Rumboldt Z; Ivancan V; Nikić N; Rudeź I; Biocina B; Sutlić Z
    Lijec Vjesn; 1995 Jun; 117 Suppl 2():32-4. PubMed ID: 8649147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Amrinone in acute and long-term therapy].
    Klepzig M; Kleinhans E; Büll U; Strauer BE
    Z Kardiol; 1985 Feb; 74(2):85-90. PubMed ID: 3922139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel approach to the development of positive inotropic agents for chronic heart failure.
    Packer M
    J Cardiovasc Pharmacol; 1995; 26 Suppl 1():S52-6. PubMed ID: 8907131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular pharmacology of 6-[4-(4'-pyridyl)aminophenyl]-4,5-dihydro-3(2H)-pyridazinone hydrochloride, a novel and potent cardiotonic agent with vasodilator properties.
    Narimatsu A; Kitada Y; Satoh N; Suzuki R; Okushima H
    Arzneimittelforschung; 1987 Apr; 37(4):398-406. PubMed ID: 3606694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.